Market Research Logo

Global Ulcerative Colitis Market 2016-2020

About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

Technavio’s analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals
Other prominent vendors
  • Abbott
  • Ajinomoto Pharmaceuticals
  • Amgen
  • Arena Pharmaceuticals
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • BioLineRx
  • Celgene
  • Cosmo Pharmaceuticals
  • Eisai
  • Ferring Pharmaceuticals
  • Galapagos
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Kaken Pharmaceutical
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lipid Therapeutics
  • Meda
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Nestlé
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Shire Pharmaceuticals
  • Sterna Biologicals
  • Tillotts Pharma
  • TopiVert
  • UCB
  • Zeria Pharmaceutical
Market driver
  • Increase in patient assistance programs
  • For a full, detailed list, view our report
Market challenge
  • Patent expiries
  • For a full, detailed list, view our report
Market trend
  • Rising use of biologics
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Ulcerative Colitis Market 2016 - 2020

Technavio recognizes the following companies as the key players in the Global Ulcerative Colitis Market: AbbVie, Janssen Biotech, Merck, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, and Zeria Pharmaceutical.

Commenting on the report, an analyst from Technavio’s team said: “A noteworthy trend to watch for in the pharmaceutical industry is the rising use of biologics. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for ulcerative colitis. They act by either blocking the interleukins or the tumor necrosis factor (TNF)-alpha. Etrolizumab, being developed by Genentech (Roche), and Stelara (ustekinumab), developed by Janssen Pharmaceuticals, are prominent biologics that are under investigation for the treatment of ulcerative colitis and are expected to be launched in the market during the forecast period.”

According to the report, a key driver for market growth is the increase in patient assistance programs. Patients who cannot afford costly treatments are provided financial assistance by state and federal agencies such as Medicaid, Medicare, and Social Security in the US. People can also apply for free medications or financial co-pay assistance for the drug Humira through AbbVie's patient assistance program. According to the Humira Complete Savings Card, the drug can be obtained for as low as $5 per month. Similarly, Janssen Pharmaceuticals has initiated programs such as JanssenAccessOne and RemiStart.

Further, the report states that expiring patents for many drugs will affect the bottom line for manufacturers and in turn, have an adverse impact on market growth.

Companies Mentioned

AbbVie, Janssen Biotech, Merck, Takeda Pharmaceuticals, Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, Zeria Pharmaceutical.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Etiology
      • Table Causes of ulcerative colitis
    • Epidemiology
    • Symptoms
      • Table Symptoms of ulcerative colitis
    • Diagnosis and testing
      • Table Diagnostic approach for ulcerative colitis
    • Treatment
      • Table Treatment options for ulcerative colitis
      • Table Treatment guidelines of ulcerative colitis based on severity
      • Table Surgical procedures to treat ulcerative colitis
    • Prognosis
    • Economic burden
    • Reimbursement scenario
  • Pipeline analysis
    • Table Global ulcerative colitis drugs market: Pipeline portfolio
    • Z-206
    • MD-0901
    • TP05
    • Stelara
    • Etrolizumab
    • Xeljanz
    • HMPL-004
    • Kappaproct
    • AJG511
    • AJM300
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global ulcerative colitis drugs market 2015-2020 ($ billions)
      • Table Snapshot of global ulcerative colitis drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by molecule type
    • Table Global ulcerative colitis drugs market by molecule type
    • Biologics
    • Small molecules
      • Table Global ulcerative colitis drugs market by molecule type 2015
    • Biologics segment in ulcerative colitis drugs market
      • Table Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
    • Small molecules segment in ulcerative colitis drugs market
      • Table Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
  • Market segmentation by dosage form
    • Table Global ulcerative colitis drugs market by dosage form
    • Solid
    • Liquid
  • Market segmentation by route of administration
    • Table Global ulcerative colitis drugs market by route of administration
    • Oral
    • Parenteral
  • Geographical segmentation
    • Global ulcerative colitis drugs market by geography 2015-2020
      • Table Global ulcerative colitis drugs market segment by geography 2015
      • Table Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
    • Ulcerative colitis drugs market in Americas
      • Table Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
    • Ulcerative colitis drugs market in EMEA
      • Table Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
    • Ulcerative colitis drugs market in APAC
      • Table Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Increase in patient assistance programs
    • High unmet needs
    • Tentative approval of candidates in pipeline
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of drugs
    • Patent expiries
    • Adverse effects of drugs
    • Unknown disease etiology
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Growing public awareness
    • Rising use of biologics
    • Emergence of biosimilars
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Global ulcerative colitis drugs market share analysis 2015
      • Table YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
    • AbbVie
      • Table AbbVie: Product segmentation by revenue 2014
      • Table AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
      • Table AbbVie: Geographical segmentation by revenue 2014
      • Table AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
      • Table AbbVie: Key takeaways
    • Janssen Biotech
      • Table Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
      • Table Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
      • Table Janssen Biotech: Key takeaways
    • Merck
      • Table Merck: Business segmentation by revenue 2014
      • Table Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Merck: Geographical segmentation by revenue 2014
      • Table Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
      • Table Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
      • Table Merck: Key takeaways
    • Takeda Pharmaceuticals
      • Table Takeda Pharmaceuticals: Business segmentation by revenue 2014
      • Table Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
      • Table Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
      • Table Takeda Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report